Literature DB >> 24955783

Post-allograft pomalidomide and reversible hepatotoxicity.

J M Pauff1, R S Gonzalez2, K P Sajnani3, A Kassim1, M Jagasia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24955783     DOI： 10.1038/bmt.2014.128

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Lenalidomide-induced severe hepatotoxicity.

Authors:  Subuhee Hussain; Royston Browne; Julie Chen; Samir Parekh
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

2.  Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

Authors:  Rohtesh S Mehta; Antonio Di Stasi; Chitra Hosing; Nina Shah; Katayoun Rezvani; Amin Alousi; Susan O'Brien; William Wierda; Michael Keating; Elizabeth J Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-27

3.  Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.

Authors:  Tereza Coman; Emmanuel Bachy; Mauricette Michallet; Gérard Socié; Madalina Uzunov; Jean Henri Bourhis; Simona Lapusan; Alain Brebion; Stéphane Vigouroux; Sébastien Maury; Sylvie François; Anne Huynh; Bruno Lioure; Ibrahim Yakoub-Agha; Olivier Hermine; Noël Milpied; Mohamad Mohty; Marie Thérèse Rubio
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

Review 4.  Lenalidomide-associated hepatotoxicity--a case report and literature review.

Authors:  Borko Nojkov; Carina Signori; Amulya Konda; Robert J Fontana
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

5.  Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

Authors:  Evelien Kneppers; Bronno van der Holt; Marie-Jose Kersten; Sonja Zweegman; Ellen Meijer; Gerwin Huls; Jan J Cornelissen; Jeroen J Janssen; Cynthia Huisman; Petra B Cornelisse; Cheryl P Bruijnen; Maarten Emmelot; Pieter Sonneveld; Henk M Lokhorst; Tuna Mutis; Monique C Minnema
Journal:  Blood       Date:  2011-06-20       Impact factor: 22.113

Review 6.  Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.

Authors:  Filipe Vilas-Boas; Regina Gonçalves; Manuel Sobrinho Simões; Joanne Lopes; Guilherme Macedo
Journal:  Gastroenterol Hepatol       Date:  2012-07-11       Impact factor: 2.102

Review 7.  Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation.

Authors:  Aiko Kida; George B McDonald
Journal:  Semin Hematol       Date:  2012-01       Impact factor: 3.851

8.  Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.

Authors:  Christine Wolschke; Thomas Stübig; Ute Hegenbart; Stefan Schönland; Marion Heinzelmann; York Hildebrandt; Francis Ayuk; Djordje Atanackovic; Peter Dreger; Axel Zander; Nicolaus Kröger
Journal:  Exp Hematol       Date:  2012-10-17       Impact factor: 3.084

9.  A Case of Drug-Induced Hepatitis due to Lenalidomide.

Authors:  M-C Zanella; L Rubbia-Brandt; E Giostra; Y Chalandon; A Hadengue; L Spahr
Journal:  Case Rep Gastroenterol       Date:  2011-04-13

10.  Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.

Authors:  A A Chanan-Khan; A Swaika; A Paulus; S K Kumar; J R Mikhael; S V Rajkumar; A Dispenzieri; M Q Lacy
Journal:  Blood Cancer J       Date:  2013-09-06       Impact factor: 11.037
  10 in total
  1 in total

Review 1.  The use of novel agents in multiple myeloma patients with hepatic impairment.

Authors:  Lindsay C Stansfield; Wilson I Gonsalves; Francis K Buadi
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.